anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective, observation study to test the central hypothesis that individuals with cystic fibrosis (CF) have a higher propensity to increased visceral adipose tissue (VAT) accumulation and decreased lean body mass (LBM) compared to healthy controls, and this dysregulation in adipose and protein deposition exacerbates glucose intolerance and lung function decline. A sub-set of participants with CF will be followed longitudinally for two years (n=40). The investigators will conduct detailed body composition, fat distribution, metabolic, and nutritional phenotyping in this cohort. Body fat distribution will be assessed with MRI. Whole body composition will be assessed with DEXA. Glucose tolerance will be assessed with an oral glucose tolerance test (OGTT) and mathematical modeling of the C-peptide and insulin response to glucose. Lung health will be assessed by objective clinical data and self-reported symptoms.
Cisplatin (cis-diamminedichloroplatinum, Platinol®) is commonly utilized in chemotherapy regimens for the treatment of solid cancers including lung, head and neck, and cervix. Its main mechanism of action is through binding of DNA to form cross-links, leading to arrest of DNA synthesis and replication. A major adverse consequence of cisplatin therapy is acute kidney injury (AKI). It is reported that between 30 and 38 percent of patients develop signs of nephrotoxicity (toxicity in the kidneys) after a single cisplatin dose, despite strategies such as hydration to limit renal exposure. This is problematic for patients as kidney injury can delay further treatment and limit the total number of chemotherapy cycles received, thereby reducing the overall efficacy of cisplatin-containing regimens. Furthermore, it is apparent that cisplatin will remain a central component to the treatment of solid tumors in the foreseeable future. New approaches to identify patients at risk of acute kidney injury (AKI) and prevent its development and progression are urgently needed. Cisplatin causes nausea and vomiting, which requires treatment with 5-HT3 antagonists (5-HT3A) to control. Associations between the clinical use of the 5-HT3A antiemetic drugs and the risk of cisplatin AKI have recently been discovered. This study will interrogate relationships between 5-HT3A drugs (granisetron, ondansetron, and palonosetron) and cisplatin AKI.
The invention discloses a metal organic framework nano particle for oral protein administration and a preparation method thereof, belonging to the technical field of pharmacy. The metal organic framework nano-particle provided by the invention can promote the oral absorption of protein/polypeptide with the molecular weight of 10000 daltons at most. The metal organic framework nano-particle is prepared by loading a nano-scale acid-resistant metal organic framework with a small-molecule protein/polypeptide drug through hydrophobic interaction and modifying a target molecule on the surface. The porous acid-resistant metal organic framework shows high drug-loading capacity for protein, strong protection, and good biocompatibility and slow and controlled release kinetics in vivo. The targeting molecule can target the receptor on the intestinal epithelial cell membrane, overcome the problem of extremely low permeation efficiency of the protein in the intestinal epithelial cell layer, and improve the oral bioavailability of the protein. The preparation method is simple and convenient, has low production cost, and is expected to realize painless, controlled release and convenient protein oral administration.
Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
Disclosed herein are systems and methods for identifying radiation therapy treatment data for patients. A processor accesses (210) a neural network trained based on a first set of data generated from characteristic values of a first set of patients that received treatment at one or more first radiotherapy machines. The processor executes (220) the neural network using a second set of data comprising characteristic values of a second set of patients receiving treatment at one or more second radiotherapy machines. The processor executes (230) a calibration model using an output of the neural network based on the second set of data to output a calibration value. The processor executes (240) the neural network using a set of characteristics of a first patient to output a first confidence score associated with a first treatment attribute. The processor then adjusts (250) the first confidence score according to the calibration value to predict the first treatment attribute.
The investigators will recruit the patients diagnosed with schizophrenia or bipolar disorder from Beijing Anding Hospital. Participants will use a mobile phone app (Huawei Health) to collect data on sleep log, daily activities and calorie consumption. The smart body fat scale with high-precision weighing chip (Huawei Scale 2pro) will be used to collect heart rate, weight, BMI, body type, basal metabolic rate, fat rate, fat free body weight, skeletal muscle mass, bone salt content, visceral fat grade, body water (%), body protein rate and body composition, and all data will be uploaded to the app. Participants could also record their daily dietary intake (for calculation of calorie intake) in the health app.

This is a 6-month, single-center, stepped wedge-shaped cluster randomized study. It is planned to recruit 200 overweight subjects, including 100 patients with schizophrenia and 100 patients with bipolar disorder, who are receiving antipsychotics,. Interventions included self-monitoring of weight using smart body fat scale, dietary management, and exercise management. The follow-up team consists of a psychiatrist, nutrition instructor, and exercise instructor who set weight loss goals and implemented a plan. The patients themselves use the health APP and smart body fat scale to record health data such as body weight; psychiatrists evaluate the patient's condition and conduct laboratory tests; nutrition instructors conduct dietary education and formulate individualized energy-limited balanced diet prescriptions; exercise instructors conduct behavioral ways and sports education, and individualized exercise prescriptions.
Pyrrolo[2,1-b]-3-benzazepines of the formula <IMAGE> and their salts, e.g. cis/trans geometrical isomers, are prepared in pure form or as mixture. The substituents are defined in Claim 1. These compounds are obtained by reacting a corresponding compound with the partial formula = CHCH2CH2-Q in which Q is a group which can be eliminated, namely halogen, a p-toluenesulphonate or methanesulphonate group, with ammonia, or with an amine which has the substituents R1 and R2. The isomers, preferably the E isomer, can be obtained from the mixture of isomers by chromatographic separation. The resulting compounds can be used as skeletal muscle relaxants or sedatives.
Midazolam hydrochloride is a water-soluble benzodiazepine available as a sterile, nonpyrogenic parenteral dosage form for intravenous or intramuscular injection. Each mL contains midazolam hydrochloride equivalent to 1 mg or 5 mg midazolam compounded with 0.8% sodium chloride and 0.01% disodium edetate, with 1% benzyl alcohol as preservative; the pH is 3 (2.5 to 3.5) and is adjusted with hydrochloric acid and, if necessary, sodium hydroxide.

Midazolam is a white to light yellow crystalline compound, insoluble in water. The hydrochloride salt of midazolam, which is formed in situ, is soluble in aqueous solutions. Chemically, midazolam HCl is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine hydrochloride. Midazolam hydrochloride has the chemical formula C18H13ClFN3•HCl, a calculated molecular weight of 362.24 and the following structural formula:
The invention relates to a traditional Chinese medicine mixture for treating pharyngitis and tonsillitis of children and a preparation method thereof. The composition is prepared from the following components in parts by weight: lithospermum, cortex lycii radicis, indigo naturalis, subprostrate sophora, rhizoma anemarrhenae, gypsum, platycodon grandiflorum, liquorice, schizonepeta and mint. The traditional Chinese medicine mixture provided by the invention aims at treating pharyngitis and tonsillitis of children, and has the effects of clearing heat and removing toxicity, cooling blood, clearing head and eyes and relieving sore throat. Can be used for treating pharyngitis and tonsillitis, and has the advantages of good therapeutic effect, rapid action, and no adverse reaction. Meanwhile, the medicines in the invention are formulated according to the traditional Chinese medicine theory, and the dosage of the medicines is strictly controlled, so that the best effect of treating children cough is achieved. The preparation method is simple and convenient to operate.
OBJECTIVE: To analyze the influencing factors of body weight retention in woman at 1 year postpartum, and to construct and evaluate a nomogram prediction model for postpartum 1-year weight retention.
METHODS: From September 2010 to February 2011, 468 pregnant women in the third trimester were recruited from Yuexiu District and Baiyun District Maternal and Child Health Hospital in Guangzhou, and followed up to 1 year postpartum. The basic demographic information of pregnant women was collected by self-made questionnaire. Dietary intake in the third trimester was investigated by 3-day 24-hour dietary review. The weight of women before delivery and one year after delivery were measured. According to whether the weight retention at 1 year postpartum is greater than 0 kg, the study subjects were divided into the 1-year postpartum weight retention group and weight recovery group. Logistic regression analysis were used to screen the influencing factors of weight retention at 1 year postpartum. R 4.2.3 software was used to construct the nomogram prediction model. The subject working characteristic curve, calibration curve, Hosmer-Lemeshow goodness of fit test and clinical decision curve were used to evaluate the model's differentiation, accuracy and clinical applicability.
RESULTS: Among 329 subjects in the model training set, the 1-year postpartum weight retention was 68.09%, and the median and quartile levels of retained body weight were 5.0(3.0, 10.0)kg. After Logistic analysis, a nomogram prediction model was constructed based on five factors: pre-pregnancy body mass index(BMI), pregnancy weight gain, parity, gravitity, 0-6 months postpartum feeding pattern. The model had good discrimination(AUC_(training)=0.778, AUC_(testing)=0.767) and accuracy(Hosmer-Lemeshow test: P_(training)=0.946, P_(testing)=0.891).
CONCLUSION: The 1-year postnatal weight retention nomogram model based on women's pre-pregnancy BMI, pregnancy weight gain, parity, gravitity, 0-6 months postpartum feeding pattern has good differentiation, accuracy and clinical applicability.
PURPOSE:To obtain a chitosan compd. having the same water retention characteristics as that of hyaluronic acid and being an optimum raw material for cosmetics and medicines by reacting 6-O-(carboxymethyl)chitosan with succinic anhydride. CONSTITUTION:One mol of 6-O-(carboxymethyl)chitosan prepd. by deacetylating 6-O-(carboxymethyl)chitin by heating in an aq. alkali soln. is reacted with 1-20mol of succinic anhydride in water and/or an org. solvent such as methanol at room temp. to 50 deg.C for 2-48hr. After the reaction is completed, the reaction mixture is neutralized and unreacted raw materials are removed therefrom by dialysis membrane treatment to obtain N-(3-carboxypropanoyl)-6- O-(carboxymethyl)chitosan of the formula (wherein M and M' are each H or alkali metal; n is 10-5,000) with little impurities.
BACKGROUND: Owing to the lack of understanding of the clinical significance of pericardial calcification during pericardiectomy, whether pericardial calcification should be considered when determining the optimal timing for pericardiectomy is debatable. We aimed to investigate the effect of pericardial calcification on early postoperative outcomes in patients who underwent pericardiectomy for constrictive pericarditis.
METHODS: Altogether, 44 patients who underwent pericardiectomy for constrictive pericarditis were enrolled. After excluding three patients who underwent concurrent surgeries, a total of 41 patients were categorized into two groups based on the presence of pericardial calcification as determined by preoperative computed tomography and pathological examination. Preoperative clinical and imaging characteristics, intraoperative data, and early postoperative outcomes were compared between the two groups. A multivariable analysis was performed to identify the factors associated with postoperative complications.
RESULTS: The group with and without PC comprised 21 and 20 patients, respectively. No significant differences were observed in 30-day mortality (n = 1 [5%]) in the group with pericardial calcification and no mortality in the group without pericardial calcification (p > 0.999). Other early postoperative outcome variables did not demonstrate any significant differences between the two groups. However, the use of cardiopulmonary bypass was associated with postoperative complications (p < 0.009, odds ratio: 63.5, 95% confidence interval: 5.13-3400).
CONCLUSIONS: Pericardial calcification did not significantly affect the postoperative outcomes after pericardiectomy. Further comprehensive studies, including those with larger sample sizes and longitudinal designs, are necessary to determine whether pericardial calcification can significantly influence the timing of surgical intervention.
BACKGROUND: Eosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic (hEOs) and inflammatory (iEOs) eosinophil subsets is unknown. We aimed to determine the relative impact of mepolizumab and benralizumab treatment on eosinophil subset and phenotype, and explore clinical associations of eosinophil subsets with severe asthma characteristics and treatment response.
METHODS: We performed a cross-sectional observational study of severe asthma (eosinophilic n = 32, non-eosinophilic n = 23, mepolizumab-treated n = 25), with longitudinal follow-up of 30 eosinophilic participants at two timepoints (4-24 weeks, >24 weeks) post-commencement of mepolizumab (n = 20) or benralizumab (n = 10). Blood hEOs and iEOs were measured by flow cytometry assessment of surface CD62L protein.
RESULTS: iEO proportion was significantly lower in mepolizumab-treated participants in both the cross-sectional and longitudinal study. Mepolizumab and benralizumab depleted iEOs to a similar extent, however a significantly greater number of hEOs remained in mepolizumab participants at follow-up. Greater iEO proportion correlated with poorer asthma control in eosinophilic but not non-eosinophilic asthma. Higher residual iEO proportion correlated with poorer asthma control in mepolizumab-treated individuals. Reduced blood eosinophil viability was observed in around half of mepolizumab-treated participants, which was associated with significantly better asthma control and spirometry.
CONCLUSIONS: Mepolizumab depletes iEOs and reduces circulating eosinophil viability in severe asthma but preserves a residual population of circulatory hEOs. In contrast benralizumab depleted both iEOs and hEOs. Higher iEO abundance and eosinophil viability are associated with poorer clinical outcomes following mepolizumab-treatment. Monitoring circulating eosinophil phenotype and viability may be useful to predict biologic treatment response in severe asthma.
The present invention relates to compositions and methods for inhibiting plaque. In particular, this invention relates to oral compositions comprising: (a) a safe and effective amount of a plaque-inhibiting carboxy starch polymer comprising the formula <IMAGE>   wherein W and X are independently selected from CH2OH, CHO and CO2H, or the neutralized carboxylic acid salts thereof, Y and Z are independently selected from CHO and CO2H, or the neutralized carboxylic acid salts thereof, n is in the range of from about 5 to about 2500, m is in the range of from 0 to about 2500, provided that the sum of n and m ranges from about 5 to about 2500, and the degree of carboxylation of said active agent ranges from about 1 to about 3; and (b) a pharmaceutically acceptable carrier. These compositions inhibit plaque without staining the teeth which are contacted with the composition. This invention also relates to a method of inhibiting plaque on tooth surfaces in the oral cavity. This method involves applying a safe and effective amount of the carboxy starch polymer active agent to the oral cavity. Such an application is typically made by applying the above-described oral compositions containing the carboxy starch polymer to the oral cavity. The application does not stain the teeth on which it is made.
The invention relates to medicine, in particular to a disinfecting agent. The agent is based on chlorine derivative of cyanuric acid and further comprises basic or acid component or a mixture thereof in definite ratio of components. The agent comprises alkali or alkali-earth salts of carbonic acid or a mixture thereof as the basic component. It comprises phosphates of alkali metals, or sodium bisulfite, or acids selected from citric, tartaric, fumaric, maleinic, adipinic, malic, sulfanic, oxalic or boric acid or alkali salts thereof or a mixture thereof as the acid component. The agent comprises a neutral filler, which is sodium sulfate, a washing component selected from sodium laurylsulfate or sulfonol, a binder selected from sodium benzoate, stearates of alkali-earth metals, or talc. The invention provides affecting upon a wide range of organisms at disinfecting operation, including spore forms.
The tableted dosage form for the delayed release of Alfusosin hydrochloride in the proximal segment of gastrointestinal tract consists of several layers: a) Layer 1 obtained by pressing the mixture or the granulate contains hydrophilic polymers (5.0-90%, preferably 10-85%) capable to absorb rapidly a large amount of water upon the contact with biological fluids. b) Layer 2 is adjacent to layer 1 and comprises the hydrophilic polymers and excipients that provides the required characteristics in the tableting process and allows for the controlled release of Alfusosin hydrochloride within the specified time. c) As a variant, layer 3 is provided. Layer 3 contains the hydrophilic gel-forming polymers that may swell or be destroyed for modifying the release of Alfusosin hydrochloride from layer 2. The layer 3 is more impermeable for active substance than layer 2. The invention relates also to the pharmaceutical formulation of Alfusosin hydrochloride tablets.
The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This international gathering focused on cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. In addition to the conference's plenary content, the agenda featured ten breakout workshops on topics of importance to the enteric vaccine field. This unique aspect of VASE Conferences allows focused groups of attendees to engage in in-depth discussions on subjects of interest to the enteric vaccine development community. In 2022, the workshops covered a range of topics. Two focused on the public health value of enteric vaccines, with one examining how to translate evidence into policy and the other on the value proposition of potential combination vaccines against bacterial enteric pathogens. Two more workshops explored new tools for the development and evaluation of vaccines, with the first on integrating antigen/antibody technologies for mucosal vaccine and immunoprophylactic development, and the second on adjuvants specifically for Shigella vaccines for children in low- and middle-income countries. Another pair of workshops covered the status of vaccines against two emerging enteric pathogens, Campylobacter and invasive non-typhoidal Salmonella. The remaining four workshops examined the assessment of vaccine impact on acute and long-term morbidity. These included discussions on the nature and severity of intestinal inflammation; cellular immunity and immunological memory in ETEC and Shigella infections; clinical and microbiologic endpoints for Shigella vaccine efficacy studies in children; and intricacies of protective immunity to enteric pathogens. This article provides a brief summary of the presentations and discussions at each workshop in order to share these sessions with the broader enteric vaccine field.
PROBLEM TO BE SOLVED: To obtain a powder effectively prevented from deteriorating in quality as a result of moisture absorption or subsequent aggregation by adding a specific amount of an ingredient having a specific moisture content which is higher by at least a specific value (%) than an intrinsic moisture content. SOLUTION: This powder contains 3-90wt.%, on a dry basis, ingredient (a) a moisture content B (glass transition moisture content at 25 deg.C) higher by at least 5wt.% than an intrinsic moisture content A (equilibrium moisture content measured at 25 deg.C in a supersaturated water vapor atmosphere). It is regulated so as to have a moisture content lower than 40wt.% based on the wet weight. Thus, the powder can be effectively prevented from being deteriorated in quality by moisture absorption, i.e., from suffering softening, aggregation, or liquefaction all caused by moisture absorption. Examples of the powder include foods such as breadcrumbs and a powdery soy sauce. Examples of the ingredient contained include various agars, several carrageenans, blood albumin, and several crosslinked starches.
Coronavirus (SARS-nCoV-2) is a member family coronaviridae, order Nidovirales. It is single-stranded, positive sense enveloped RNA discovered in early 1960s. Coronavirus pandemic put a lot of lives at stake. By 19 March 2020, a total of 219238 confirmed cases with 8967 being dead and 85742 recovered cases have been reported. Worldwide, in 9 days, the confirmed death cases have been doubled. The average death rate of Covid-19 per day is approximately 88 patients as of the given date. Unlike, SARS-CoV and MERS-CoV, the disease progression and mortality rate of Covid-19 is startling. The pre-pathogenic course of novel Covid-19 is yet to be determined, so the risk factors, clinical picture and medical intervention too. Only supportive therapy is being practised. Yet many trials of antimalarial drug, chloroquine and quinolone is currently taking place worldwide. According to Cortegiani A, 23 ongoing trials from China have been registered. Clinical experience from recent Wuhan epidemic came up with promising results of chloroquine and hydroxychloroquine in Covid-19 positive patients. Some in-vitro studies suggest that these immunomodulant drugs can interfere with SARS-nCov-2 replication. These are federal drug authority approved medicine for malaria. Yet their effectiveness and safety in treating Covid-19 pneumonia is a question mark.